Blanket Purchase Agreement W81K0020A0003

Award Date 3/6/20
Last Date to Order 3/31/25
Funding Federal Agency
Defense Health Agency
Contracting Federal Agency
Medical Command
Ultimate Awardee
Not listed
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Blanket Purchase Agreement was awarded by the Department of the Army Medical Command to Nephron Sterile Compounding Center LLC on March 1, 2020, with a potential value of $2.5 million. The BPA is for specialized compounded intravenous solutions with no set-aside used. The period of performance extends through the last date to order of September 30, 2023. The BPA facilitates recurring orders for specific pharmaceutical products and supplies, including Phenylephrine HCI Injection,...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Civica Inc., a non-profit organization and manufacturer of goods. The BPA has a ceiling value of $625,000.00 and a period of performance ending on April 3, 2026. The BPA is for the procurement of the pharmaceutical products daptomycin, lorazepam, phenylephrine, and anectine. As a BPA, this contract vehicle allows the agency to place individual task orders for these products as needed...
This Blanket Purchase Agreement was awarded by the Department of the Army Medical Command to Pharmedium Services, LLC for specialized compounded intravenous solutions. The potential value of the BPA is $2.5 million. The period of performance is from October 1, 2018 through September 30, 2023. The BPA will facilitate orders for various pharmaceutical supplies to support pharmacy operations at Tripler Army Medical Center in Hawaii. Products included under the BPA are OR syringes, pre-mixed...
The Defense Health Agency awarded a blanket purchase agreement to The Compounding Center Inc. to provide various pharmaceutical supplies and compounded medications. Under four firm fixed price call contracts valued between $25,000 to $150,000 placed against the agreement, the contractor will deliver shortage pharmaceuticals, compounded drugs, and chemical compounds to Walter Reed National Military Medical Center in Bethesda, Maryland. Performance is scheduled to take place through various...
The National Acquisition Center of the U.S. Department of Veterans Affairs (VA) has awarded a $32,500,000 Blanket Purchase Agreement (BPA) to Ardelyx, Inc., a pharmaceutical company, for the supply of XPHOZAH (tenapanor), a medication used to treat hyperphosphatemia in patients on dialysis. This single-award BPA, which has an ultimate completion date of April 29, 2026, allows VA medical centers nationwide to efficiently procure the XPHOZAH medication as needed through delivery orders. Ardelyx,...
This Blanket Purchase Agreement (BPA) was awarded by the Defense Health Agency (DHA), a component of the Department of Defense, to Zuellig Pharma LTD, a prime contractor based in Asia. The single-award BPA, valued at up to $3,000,000, provides a mechanism for the DHA to procure a variety of consumable medical supplies and laboratory equipment maintenance services in support of its operations in Thailand. Task orders issued against the BPA to date total over $100,000 and cover the delivery of...
This Blanket Purchase Agreement (BPA) was awarded by the Defense Health Agency (DHA), a defense agency within the U.S. Department of Defense, to Zuellig Pharma LTD, a prime contractor based in Asia. The single-award BPA has a ceiling value of $1,216,000 and an ultimate completion date of September 5, 2029. The BPA is for the provision of laboratory reagents and medical supplies to support the DHA's operations. This includes the delivery of consumable medical products such as vacutainers, test...
This Blanket Purchase Agreement (BPA) was awarded by the Defense Health Agency (DHA), a defense agency, to Lipomed, Inc., a foreign-owned for-profit organization, on September 7, 2022. The contract has a ceiling value of $500,000.00 and a period of performance ending on September 8, 2027. The BPA is for the procurement of "LIPOMED - DRUGS & BIOLOGICALS." No additional details about the specific products or services being acquired were provided in the information given. The contract...
The Defense Health Agency has awarded a Blanket Purchase Agreement (BPA) contract to Wells Pharma of Houston LLC, a for-profit limited liability company, to provide PREFILLED SYRINGES for the Naval Hospital Pensacola, FL. The single-award BPA has a potential value of $250,000.00 and a period of performance ending on August 31, 2028. As a BPA, this contract allows the agency to place orders for the specified prefilled syringes as needed over the contract term, rather than a one-time...
Central Admixture Pharmacy Services, Inc. (CAPS), a provider of compounded sterile preparations and pharmacy services, has been awarded a $6.5 million Blanket Purchase Agreement (BPA) by the Defense Health Agency (DHA). Under this IDV, CAPS will deliver a variety of compounded admixture medicines, total parenteral nutrition, and other sterile pharmaceutical products to support DHA medical programs. The contract has a period of performance through July 14, 2026, with no set-aside designation....
  • W81K0020A0003
    Blanket Purchase Agreement
  • 4
    Federal Contract Awards

The government has awarded a Blanket Purchase Agreement (BPA) to Nephron Sterile Compounding Center LLC, a woman-owned limited liability company, to provide pharmaceutical products and supplies to the Defense Health Agency (DHA). The BPA has a ceiling value of $4,000,000 and a period of performance through March 31, 2025.

Under this BPA, Nephron has received two specific task orders to date. The first is a $20,625 firm fixed price award for various injectable pharmaceutical products including Phenylephrine Hydrochloride, Succinylcholine Chloride, and preservative-free Rocuronium Bromide, with a period of performance through September 30, 2023. The second is a $12,000 firm fixed price award for Buffered Lidocaine Buffer in Sodium Bicarbonate, as well as other unspecified pharmaceutical products and supplies, also through September 30, 2023. Both task orders are for deliveries to be made to DHA's facilities in Cayce, South Carolina. No set-aside designations were used for these awards made under the existing BPA vehicle.

Generated 7/11/24, 9:14 AM